Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD

Margherita Nosadini, MD, PhD, Michael Eyre, MD, Thea Giacomini, MD, Massimiliano Valeriani, MD, Marida Della Corte, MD, Andrea D. Pratico, MD, Pietro Annovazzi, MD, Ramona Cordani, MD, Duccio Maria Cordelli, MD, PhD, Giovanna Cricchiuti, MD, Gabriella Di Rosa, MD, Valentina Dolcemascolo, MD, Anna Fetta, MD, Elena Freri, MD, Paolo Gallo, MD, PhD, Matteo Gastaldi, MD, PhD, Tiziana Granata, MD, Luisa Graziani, MD, Raffaele Iorio, MD, PhD, Martina Lombardini, MD, Monica Margoni, MD, PhD, Sara Mariotti, MD, PhD, Sara Matricardi, MD, PhD, Federico Melani, MD, Nardo Nardocci, MD, PhD, Laura Papetti, MD, Alice Passarini, MD, Francesco Pisani, MD, Chiara Po', MD, Marco Putneparampil, MD, PhD, Francesca Ragona, MD, Salvatore Savasta, MD, PhD, Sabrina Siliquini, MD, Irene Toldo, MD, PhD, Alessandra Tozzo, MD, Emanuela Claudia Turco, MD, Antonio Varone, MD, Alberto Vogrig, MD, Luigi Zuliani, MD, PhD, Samuela Bugin, MD, Sara Rossato, MD, PhD, Alessandro Orsini, MD, Gaetano Cantalupo, MD, PhD, Maria Margherita Mancardi, MD, Michela Ada Noris Ferrilli, MD, Thomas Foiadelli, MD, and Stefano Sartori, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2023;10:e200065. doi:10.1212/NXI.0000000000200065

Abstract

Background and Objectives
We sought to identify early factors associated with relapse and outcome in paediatric-onset myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD).

Methods
In a multicenter retrospective cohort of pediatric MOGAD (≤18 years), onset features and treatment were compared in patients with monophasic vs relapsing disease (including cases with follow-up ≥12 months after onset or relapse at any time) and in patients with final Expanded Disability Status Scale (EDSS) 0 vs ≥1 at last follow-up (including cases with follow-up >3 months after last event or EDSS0 at any time). Multivariable logistic regression models were used to evaluate factors associated with relapsing disease course and EDSS ≥1 at final follow-up.

Results
Seventy-five children were included (median onset age 7 years; median 30 months of follow-up). Presentation with acute disseminated encephalomyelitis was more frequent in children aged ≥5 years, and was more frequent in children aged ≤5 years. Higher baseline Expanded Disability Status Scale (EDSS) was associated with lower likelihood of relapse. Early immunotherapy and longer corticosteroid treatment were associated with lower risk of relapsing disease course and EDSS ≥1 at final follow-up.
Glossary

ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; CBA = cell-based assay; EEG = electroencephalography; EDSS = Expanded Disability Status Scale; MOGAD = myelin oligodendrocyte glycoprotein antibody–associated disorder; NfL = neurofilament light chain; NMOSD = neuromyelitis optica spectrum disorder; OCB = oligoclonal bands; ON = optic neuritis; TM = transverse myelitis.

Discussion

At first attack of pediatric MOGAD, early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI seem associated with lower risk of relapse, whereas higher disease severity is associated with greater risk of final disability (EDSS ≥ 1).

Myelin oligodendrocyte glycoprotein (MOG) is a protein expressed in mature oligodendrocytes, located in the outermost layer of myelin sheath in the CNS. MOG antibody–associated disorders (MOGADs) define a subgroup of CNS inflammatory–acquired demyelinating syndromes distinct from MS\(^1-6\) and aquaporin-4 (AQP4) positive neuromyelitis optica spectrum disorder (NMOSD),\(^7,8\) typically including CNS clinical syndromes such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis (TM), and AQP4-seronegative NMOSD.\(^5,9\) Besides, atypical presentations have been more recently described, such as encephalitis and isolated seizures in the absence of CNS demyelination (or with predominant cortical/subcortical rather than white matter involvement) and more severe leukodystrophy-like phenotypes.\(^5,10-13\)

MOGADs have a relapsing course in approximately 40%–56% of adults and in 27%–53% of children.\(^6,7,11,14-17\) The persistence of positive MOG antibodies at follow-up has been repeatedly, although not invariably, reported to be associated with higher risk of a relapsing disease course.\(^2,4,6,8,11,14-16,18-22\) However, current data do not allow a proper prediction of disease course or final outcome at MOGAD onset.\(^6,17,20,21,23-26\)

In this Italian multicenter cohort of pediatric MOGAD, we strove to identify early clinical-paraclinical factors at disease onset associated with subsequent relapse and final outcome, with particular focus on modifiable factors such as treatment.

Methods

Inclusion Criteria and Data Collection

Patients with MOGAD (defined as positive serum MOG antibodies and at least 1 clinical event consistent with a MOGAD phenotype, as detailed below) and onset in pediatric age (aged 18 years or younger) in Italy were included. Data were collected retrospectively between November 2016 and August 2022, using a structured questionnaire filled in by the treating physician.

Operational Definitions

MOGAD syndromes were categorized as diagnosed by the treating physicians and defined according to the most recent available criteria and definitions including ADEM,\(^27\) ON,\(^28\) TM,\(^29\) NMOSD,\(^30,31\) clinically isolated syndrome,\(^27\) and encephalitis.\(^11,13,32,33\) Relapsing phenotypes were defined as either relapsing ADEM, ON, TM, or NMOSD; ADEM-ON (ADEM followed by ON)\(^5,34,35\); or relapsing CNS demyelination (relapsing MOGAD not falling into any of the other categories). Patients with MOG antibodies and final diagnosis MS\(^36\) were excluded from the present cohort.

Relapses were defined as a new clinical episode occurring at least 1 month after the last acute attack\(^5\) or, in the case of ADEM, at least 3 months after onset of the previous episode.\(^11,27\) Disease course was categorized as monophasic or relapsing (≥2 total disease events including onset).
In the acute phase, investigations were performed based on available reports (brain MRI, CSF, and MOG antibody testing). Data on MOG antibody assay were collected, although diagnosis through live cell-based assay (CBA), currently the gold standard, was not a mandatory requirement for inclusion.

Overall duration of immunotherapy at first MOGAD event (onset) was recorded; in case of relapse while on immunotherapy, duration of treatment was considered as the time on immunotherapy at first MOGAD event until relapse. In case of rituximab, treatment duration was operatively considered to be prolonged for 6 months after rituximab initiation (or until B-cell repopulation if available).

This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline for cohort studies.

**Statistical Analysis**

Data collection was subject to data availability; therefore, in the Results, denominators may differ. Clinical features and treatment factors at first MOGAD event were compared in patients with monophasic disease course (defined as absence of relapse after at least 12-month follow-up) vs relapsing course (relapse at any time) and in patients with EDSS ≥1 (including only patients with follow-up >3 months after last event) vs EDSS 0 at last follow-up (after any time).

The Mann-Whitney U test was used to test for group differences in continuous and ordinal data and the Chi square or Fisher exact test for binary data as appropriate.

A multivariable logistic regression model was used to evaluate the independent effects of prespecified variables of interest on monophasic vs relapsing disease course. Predictor variables were age at disease onset, sex, abnormal brain on MRI at first disease event, abnormal optic nerve(s) on MRI at first disease event, abnormal spine on MRI at first disease event, time from disease onset to first immunotherapy, duration of corticosteroid treatment at first disease event, and use of additional noncorticosteroid treatments. To maximise the number of cases that could be included in the model, MRI spine was assumed to be normal in patients in whom it was not undertaken (i.e., those without any clinical signs or symptoms suggestive of myelitis). Continuous variables (age at disease onset, time to first immunotherapy, duration of corticosteroid treatment) were binarized: The binarization threshold for age was set at 12 years to align with the recent literature, and the binarization thresholds for time to first immunotherapy and duration of corticosteroid treatment were set at the midpoint between the medians of the monophasic and relapsing groups. Kaplan-Meier curves for relapse-free survival were plotted and subgroup comparisons (selected according to significance in the multivariable model) conducted with univariate Cox proportional hazards regression.

A second logistic regression model was used to evaluate the independent effects of the same predictor variables on EDSS ≥1 vs EDSS 0 at final follow-up, with 2 additional predictor variables also included: relapsing vs monophasic disease course and worst EDSS at first disease event (entered as a continuous variable).

The significance threshold was set at p < 0.05 for all statistical tests. Statistical analysis used Python 3.8 with scipy.stats, statsmodels, and lifelines.

**Data Availability**

Anonymized data not published within this article will be made available by request from any qualified investigator.
Worst EDSS at first event was median 3.8 (mean 4.2, range 1–8.5, data available in 68/75). None of the patients required admission to the intensive care unit at onset (0%, 0/75).

Investigations at First MOGAD Event
At onset, brain MRI disclosed parenchymal lesions in 73.6% (53/72), more frequently in children aged 8 years or younger at onset (90.2%, 37/41) than in older patients (51.6%, 16/31) (p < 0.001). Optic nerve involvement at first MRI was detected in 48.6% (35/72), slightly more frequently in female patients (59.0%, 23/39) than in male patients (36.4%, 12/33) (p = 0.056) (bilateral optic nerve involvement in 57.1%, 20/35; longitudinal optic nerve involvement for ≥ half of its length in 50.0%, 17/34; optic nerve head swelling in 34.3%, 12/35; chiasma involvement in 25.7%, 9/35). Spine MRI at onset was abnormal in 41.8% (23/55) (longitudinally extensive TM extending over ≥3 vertebral segments in 52.2%, 12/23), only slightly less frequently in children aged 8 years or younger at onset (36.1%, 13/36) than in older patients (52.6%, 10/19) (p = 0.238).

CSF was abnormal (pleocytosis and/or CSF-restricted oligoclonal bands [OCBs]) in 60.0% (36/60). CSF-restricted OCBs were slightly more frequent in children aged 8 years or younger at onset (22.6%, 7/31) than in older patients (8.0%, 2/25) (p = 0.140).

EEG was abnormal in 71.4% (30/42) of cases (slow or disorganized activity in 64.3%, 27/42; epileptic activity in 16.7%, 7/42; recorded seizures in 4.8%, 2/42; recorded status epilepticus in 2.4%, 1/41).

In patients with available data on MOG antibody assay (94.7%, 71/75), CBAs were used in all (live CBA in 59/71, fixed CBA in 9/71, CBA not otherwise specified in 3/71).27 MOG antibody titres and follow-up MOG antibody tests were not homogeneously available and therefore were not analyzed. In a subset of patients with available data on both serum and CSF MOG antibodies (14/75), 64.3% (9/14) had positive serum and negative CSF antibodies, and 35.7% (5/14) had positive serum and CSF antibodies.

Treatment at First MOGAD Event
96.0% (72/75) of patients received immunotherapy at first event: 74.7% (56/75) corticosteroids only, 16.0% (12/75) corticosteroids plus IVIG only, and 5.3% (4/75) corticosteroids plus other combinations of immunotherapy (plasma exchange and/or rituximab and/or mycophenolate mofetil, with or without additional IVIG).

Immunotherapy was started median 5.5 days after symptom onset (mean 9.4, range 0–75; data available in 66/75). The proportion of patients who received immunotherapy <7 days from symptoms onset was significantly lower among patients with disease onset in the years 2008–2013 (11.1%, 1/9) compared with those who presented in the years 2014–2022.
|        | Total cohort (n = 75) | Monophasic (n = 39) | Relapsing (n = 26) | p Value |        | Final EDSS 0 (n = 56) | Final EDSS ≥1 (n = 15) | p Value |
|--------|----------------------|---------------------|-------------------|---------|--------|----------------------|------------------------|---------|
| **Demographics** |                      |                     |                   |         |        |                      |                        |         |
| Female patients | 40/75 (53.3%) | 20/39 (51.3%) | 15/26 (57.7%) | 0.612 | 31/56 (55.4%) | 6/15 (40.0%) | 0.290 |
| White race | 64/72 (88.9%) | 35/38 (92.1%) | 21/24 (87.5%) | 0.669 | 50/55 (90.9%) | 12/13 (92.3%) | 1.000 |
| Age at onset (y) | Median 7, mean 7.7, range 1.8–18.6 (d.a. 75/75) | Median 6.9, mean 7.3, range 1.8–15.3 (d.a. 39/39) | Median 7.4, mean 7.6, range 2.1–18.6 (d.a. 26/26) | 0.995 | Median 6.3, mean 7.1, range 1.8–18.6 (d.a. 56/56) | Median 9.7, mean 9.1, range 3.4–15.3 (d.a. 15/15) | 0.042 |
| ≥12 years | 12/75 (16.0%) | 4/39 (10.3%) | 4/26 (15.4%) | 0.703 | 6/56 (10.7%) | 4/15 (26.7%) | 0.202 |
| **Type of first MOGAD event** |                      |                     |                   |         |        |                      |                        |         |
| ADEM | 38/75 (50.7%) | 16/39 (41.0%) | 16/26 (61.5%) | 0.105 | 29/56 (51.8%) | 7/15 (46.7%) | 0.725 |
| ON (±CNS lesions) | 28/75 (37.3%) | 16/39 (41.0%) | 8/26 (30.8%) | 0.401 | 21/56 (37.5%) | 5/15 (33.3%) | 0.766 |
| NMOSD | 2/75 (2.7%) | 2/39 (5.1%) | 0/26 (0.0%) | 0.513 | 1/56 (1.8%) | 1/15 (6.7%) | 0.380 |
| CIS | 4/75 (5.3%) | 2/39 (5.1%) | 2/26 (7.7%) | 1.000 | 3/56 (5.4%) | 1/15 (6.7%) | 1.000 |
| Encephalitis (±ON) | 2/75 (2.7%) | 2/39 (5.1%) | 0/26 (0.0%) | 0.513 | 2/56 (3.6%) | 0/15 (0.0%) | 1.000 |
| Isolated LETM | 1/75 (1.3%) | 1/39 (2.6%) | 0/26 (0.0%) | 1.000 | 0/56 (0.0%) | 1/15 (6.7%) | 0.211 |
| **Severity at first MOGAD event** |                      |                     |                   |         |        |                      |                        |         |
| Worst EDSS at first event | Median 3.8, mean 4.2, range 1–8.5 (d.a. 68/75) | Median 3.3, mean 4.3, range 1–8.5 (d.a. 38/39) | Median 3, mean 4.1, range 1–8.5 (d.a. 21/26) | 0.623 | Median 3, mean 4, range 1–8.5 (d.a. 51/56) | Median 7, mean 5.1, range 3–8 (d.a. 14/15) | 0.072 |
| EDSS ≥4 | 34/68 (50.0%) | 17/38 (44.7%) | 10/21 (47.6%) | 0.832 | 22/51 (43.1%) | 10/14 (71.4%) | 0.061 |
| **Investigations at MOGAD onset** |                      |                     |                   |         |        |                      |                        |         |
| Abnormal brain MRI | 53/72 (73.6%) | 28/39 (71.8%) | 18/23 (78.3%) | 0.574 | 42/55 (76.4%) | 8/13 (61.5%) | 0.306 |
| Abnormal optic nerves on MRI | 35/72 (48.6%) | 25/39 (64.1%) | 7/23 (30.4%) | 0.010 | 26/55 (47.3%) | 7/13 (53.8%) | 0.670 |
| Abnormal spine MRI | 23/55 (41.8%) | 13/35 (37.1%) | 7/12 (58.3%) | 0.200 | 17/46 (37.0%) | 5/7 (71.4%) | 0.113 |
| Abnormal CSF | 36/60 (60.0%) | 18/33 (54.5%) | 11/18 (61.1%) | 0.651 | 30/47 (63.8%) | 4/10 (40.0%) | 0.287 |
| CSF white blood cells >4 μL | 35/58 (60.3%) | 18/32 (56.3%) | 10/18 (55.6%) | 0.962 | 29/46 (63.0%) | 4/9 (44.4%) | 0.459 |
| CSF-restricted OCBs | 9/56 (16.1%) | 5/33 (15.2%) | 3/14 (21.4%) | 0.679 | 7/43 (16.3%) | 2/10 (20.0%) | 1.000 |
| CSF proteins >45 mg/dL | 7/58 (12.1%) | 5/32 (15.6%) | 1/17 (5.9%) | 0.650 | 4/45 (8.9%) | 2/10 (20.0%) | 0.298 |

Continued
|                        | Total cohort (n = 75) | Monophasic (n = 39)<sup>a</sup> | Relapsing (n = 26)<sup>a</sup> | p Value | Final EDSS 0 (n = 56)<sup>b</sup> | Final EDSS ≥1 (n = 15)<sup>b</sup> | p Value |
|------------------------|-----------------------|----------------------------------|--------------------------------|----------|-----------------------------------|-----------------------------------|----------|
| Abnormal EEG           | 30/42 (71.4%)         | 15/21 (71.4%)                    | 9/15 (60.0%)                   | 0.473    | 23/32 (71.9%)                     | 6/8 (75.0%)                       | 1.000    |
| Slow or disorganized   | 27/42 (64.3%)         | 13/21 (61.9%)                    | 8/15 (53.3%)                   | 0.607    | 21/32 (65.6%)                     | 5/8 (62.5%)                       | 1.000    |
| activity               |                       |                                  |                                |          |                                   |                                   |          |
| Epileptic activity     | 7/42 (16.7%)          | 4/21 (19.0%)                     | 2/15 (13.3%)                   | 1.000    | 5/32 (15.6%)                      | 2/8 (25.0%)                       | 0.611    |
| IT at MOGAD onset      |                       |                                  |                                |          |                                   |                                   |          |
| Any immunotherapy (IT) | 72/75 (96.0%)         | 39/39 (100.0%)                   | 24/26 (92.3%)                  | 0.156    | 53/56 (94.6%)                     | 15/15 (100.0%)                    | 1.000    |
| Intravenous corticosteroids (CS) | 71/75 (94.7%) | 39/39 (100.0%)                   | 23/26 (88.5%)                  | 0.060    | 53/56 (94.6%)                     | 14/15 (93.3%)                     | 1.000    |
| Oral corticosteroids (CS) | 57/75 (76.0%)    | 31/39 (79.5%)                    | 19/26 (73.1%)                  | 0.548    | 42/56 (75.0%)                     | 11/15 (73.3%)                     | 1.000    |
| Intravenous immunoglobulin | 13/75 (17.3%)      | 7/39 (17.9%)                     | 3/26 (11.5%)                   | 0.728    | 9/56 (16.1%)                      | 3/15 (20.0%)                      | 0.708    |
| Therapeutic plasma exchange | 2/75 (2.7%)       | 2/39 (5.1%)                      | 0/26 (0.0%)                    | 0.513    | 1/56 (1.8%)                       | 1/15 (6.7%)                       | 0.380    |
| Rituximab              | 2/75 (2.7%)           | 2/39 (5.1%)                      | 0/26 (0.0%)                    | 0.513    | 1/56 (1.8%)                       | 1/15 (6.7%)                       | 0.380    |
| Mycophenolate mofetil  | 2/75 (2.7%)           | 2/39 (5.1%)                      | 0/26 (0.0%)                    | 0.513    | 1/56 (1.8%)                       | 1/15 (6.7%)                       | 0.380    |
| ≥2 different ITs (= CS + other IT) | 16/75 (21.3%)   | 10/39 (25.6%)                    | 3/26 (11.5%)                   | 0.164    | 12/56 (21.4%)                     | 3/15 (20.0%)                      | 1.000    |
| Days from onset to first IT (any) | Median 5.5, mean 9.4, range 0–75 (d.a. 66/75) | Median 5.5, mean 7.2, range 0–75 (d.a. 36/39) | Median 10, mean 11.6, range 1–40 (d.a. 21/26) | 0.014 | Median 5, mean 9.8, range 0–75 (d.a. 51/56) | Median 6.5, mean 8.1, range 1–15 (d.a. 12/15) | 0.380 |
| Any IT <7 days from onset | 37/69 (53.6%)      | 26/36 (72.2%)                    | 7/23 (30.4%)                   | 0.002    | 30/54 (55.6%)                     | 6/12 (50.0%)                      | 0.727    |
| Duration of CS (wk)    | Median 5, mean 7.6, range 0–48 (d.a. 75/75) | Median 6, mean 9.7, range 1–48 (d.a. 39/39) | Median 3.8, mean 5.1, range 0–27 (d.a. 26/26) | 0.014 | Median 5, mean 8.3, range 0–48 (d.a. 56/56) | Median 5, mean 5.8, range 0.5–24 (d.a. 15/16) | 0.325 |
| ≥4 weeks              | 52/75 (69.3%)         | 32/39 (82.1%)                    | 13/26 (50.0%)                  | 0.006    | 40/56 (71.4%)                     | 9/15 (60.0%)                      | 0.530    |
| ≥5 weeks              | 47/75 (62.7%)         | 29/39 (74.4%)                    | 12/26 (46.2%)                  | 0.021    | 37/56 (66.1%)                     | 8/15 (53.3%)                      | 0.363    |
| Duration of overall IT (any) (wk) | Median 5, mean 11.9, range 0–248 (d.a. 75/75) | Median 6, mean 17.8, range 1–248 (d.a. 39/39) | Median 3.8, mean 5.2, range 0–27 (d.a. 26/26) | 0.009 | Median 5.5, mean 12.5, range 0.5–108 (d.a. 15/15) | Median 5, mean 11.6, range 0.5–108 (d.a. 15/15) | 0.376 |
| ≥4 weeks              | 52/75 (69.3%)         | 32/39 (82.1%)                    | 13/26 (50.0%)                  | 0.006    | 40/56 (71.4%)                     | 9/15 (60.0%)                      | 0.530    |
| Final diagnosis        | ADEM (Mono/Rel)       | 30/75 (40.0%)                    | 16/39 (41.0%)                  | 0.401    | 24/56 (42.9%)                     | 5/15 (33.3%)                      | 0.505    |

Continued
|      | Total cohort (n = 75) | Monophasic (n = 39) | Relapsing (n = 26) | p Value | A. Final EDSS 0 (n = 56) | Final EDSS ≥1 (n = 15) | p Value |
|------|----------------------|---------------------|-------------------|---------|--------------------------|--------------------------|---------|
| ON (± CNS lesions) (Mono/Rel) | 27/75 (36.0%) | 65/39 (41.0%) | 7/26 (26.9%) | 0.244 | 21/56 (37.5%) | 4/15 (26.7%) | 0.435 |
| CNS demyelination (Rel) | 6/75 (8.0%) | 0/39 (0.0%) | 6/26 (23.1%) | n/a | 3/56 (5.4%) | 3/15 (20.0%) | 0.104 |
| ADEM-ON (Rel) | 4/75 (5.3%) | 0/39 (0.0%) | 4/26 (15.4%) | n/a | 3/56 (5.4%) | 0/15 (0.0%) | 1.000 |
| NMOSD (Mono/Rel) | 3/75 (4.0%) | 2/39 (5.1%) | 1/26 (3.8%) | 1.000 | 1/56 (1.8%) | 2/15 (13.3%) | 0.111 |
| CIS (Mono) | 2/75 (2.7%) | 2/39 (5.1%) | 0/26 (0.0%) | n/a | 2/56 (3.6%) | 0/15 (0.0%) | 1.000 |
| Encephalitis (Mono) | 2/75 (2.7%) | 2/39 (5.1%) | 0/26 (0.0%) | n/a | 2/56 (3.6%) | 0/15 (0.0%) | 1.000 |
| Isolated LETM (Mono) | 1/75 (1.3%) | 1/39 (2.6%) | 0/26 (0.0%) | n/a | 0/56 (0.0%) | 1/15 (6.7%) | 0.211 |

**Outcome**

| Length of follow-up (mo) | Median 30, mean 40.9, range 1–130 (d.a. 75/75) | Median 29, mean 38.9, range 12–122 (d.a. 39/38) | Median 51.5, mean 57.9 range 18–130 (d.a. 26/26) | 0.007 | Median 30, mean 39.2, range 4–126 (d.a. 56/56) | Median 39, mean 50.1, range 5–130 (d.a. 15/15) | 0.205 |
| Relapsing course (≥2 total events) | 26/65 (40.0%) | 0/39 (0.0%) | 26/26 (100.0%) | n/a | 15/49 (30.6%) | 9/14 (64.3%) | 0.022 |
| Relapsing course (≥3 total events) | 16/65 (24.6%) | 0/39 (0.0%) | 16/26 (61.5%) | n/a | 7/49 (14.3%) | 7/14 (50.0%) | 0.009 |
| Total number of disease events | Median 1, mean 1.9, range 1–8 (d.a. 65/65) | Median 3, mean 3.3, range 2–8 (d.a. 26/26) | n/a | Median 1, mean 1.5, range 1–5 (d.a. 49/49) | Median 2.5, mean 3.1, range 1–8 (d.a. 14/14) | 0.005 |
| EDSS at last follow-up | Median 0, mean 0.4, range 0–4 (d.a. 71/71) | Median 0, mean 0.2, range 0–4 (d.a. 39/39) | Median 0, mean 0.7, range 0–3 (d.a. 24/24) | 0.023 | 0 | Median 1.8, mean 1.8, range 1–4 (d.a. 15/15) | n/a |
| EDSS ≥1 | 15/71 (21.1%) | 5/39 (12.8%) | 9/24 (37.5%) | 0.022 | 0/56 (0.0%) | 15/15 (100%) | n/a |
| EDSS ≥2 | 7/71 (9.9%) | 2/39 (5.1%) | 5/24 (20.8%) | 0.095 | 0/56 (0.0%) | 7/14 (46.7%) | n/a |

**Abbreviations:** ADEM = acute disseminated encephalomyelitis; ADEM-ON = ADEM followed by optic neuritis; CIS = clinically isolated syndrome; CNS = CNS; CS = corticosteroid; CSF = CSF; d.a. = data available; EDSS = Expanded Disability Status Scale; EEG = electroencephalography; IgG = immunoglobulin G; IT = immunotherapy; LETM = longitudinally extensive transverse myelitis; Mono = monophasic; Mono/Rel = monophasic or relapsing; MOGAD = myelin oligodendrocyte glycoprotein antibody–associated disorder; NMOSD = neuromyelitis optica spectrum disorder; n/a, statistical test not applicable; OCBs = oligoclonal bands; ON = optic neuritis; Rel = relapsing.

Bold indicates statistically significant values at univariate analysis.

*For the study of monophasic vs relapsing disease, only patients with follow-up duration ≥12 months from onset (or with relapse at any time) were included in the analysis (65/75).

*For the study of patients with final EDSS 0 vs ≥1, only patients with available follow-up of >3 months after last event (or with EDSS 0 at any time) were included in the analysis (71/71).

*Other races were Asian (5/72) and Black or African American (3/72); data not available in 3/75.

*The presence of CSF-restricted oligoclonal bands (OCBs) was recorded.49

Among the 9/56 patients with CSF-restricted OCBs, 2/9 had 1 single band. Additional 7/56 patients had identical serum and CSF OCBs in CSF (mirror pattern).
(52.2% 36/60) \( (p = 0.010) \). Median duration of immunotherapy after the first event was 5 weeks (mean 11.9, range 0–248; data available in 75/75) and ≥4 weeks in 69.3% (52/75). In this latter subgroup of patients, the immunotherapy used for ≥4 weeks was corticosteroids in 100% (52/52), with additional plasma exchange, IVIG, rituximab, and/or mycophenolate mofetil in 25.0% (13/52).

**Disease Course and Final Outcome**

40.0% (26/65) of patients had a relapsing disease course. A total of 87 clinical events occurred in 26 relapsing patients, including onset events (median 3 events/patient, mean 3.3, range 2–8; data available in 26/26). 61.5% (16/26) of relapsing patients had more than one relapse (≥3 total disease events). The first relapse occurred at median 6.5 months after onset (mean 15.6, range 1–80; data available in 26/26). Time to first relapse was longer in children aged 8 years or younger than in older patients (median 18 vs 4 months) \( (p = 0.013) \) (eTable 1, links. lww.com/NXI/A764), and short-term relapses (≤6 months of onset) occurred less frequently in children aged 8 years or younger (3/15, 20.0%) than in older patients (9/11, 81.8%) \( (p = 0.002) \). At first relapse, 96.2% (25/26) of patients received immunotherapy: 46.2% (12/26) corticosteroids only, 19.2% (5/26) corticosteroids plus IVIG only, 11.5% (3/26) IVIG only, and 19.2% (5/26) corticosteroids plus other combinations of immunotherapy (rituximab and/or azathioprine and/or mycophenolate mofetil, with or without additional IVIG).

At last follow-up, EDSS in the total cohort was median 0 (mean 0.4, range 0–4; data available in 71/71); 78.9% (56/71) had EDSS 0. Of the 15/69 patients with final EDSS ≥1, data on the type of residual deficits were available in 14/15: visual sequelae in 7/14 (mild in 4/7), motor sequelae in 4/15 (gait disturbances 1/4, tremor or other movement disorder 3/4), epilepsy in 4/14 (ongoing antiseizure medications at last follow-up 3/4), cognitive difficulties in 4/14 (IQ in the lower range 2/4, IQ below normal range 1/4, school difficulties 1/4), behavioral or psychiatric issues in 4/14 (oppositional behaviour 2/4, mood disorder 2/4), and other in 2/15 (urinary sphincter problems 1/2, sensory sequelae 1/2).

The most frequent final diagnoses were monophasic or relapsing ADEM (40.0%, 30/75) and monophasic or relapsing ON (36.0%, 27/75) (Table 1A).

**Clinical Features and Treatment Factors Associated With Relapsing Disease Course**

**Univariate Comparison**

In the univariate comparisons of monophasic vs relapsing disease course patients (Table 1B), those with relapsing disease course had a longer interval from symptom onset to first initiation of immunotherapy (median 10 vs 5 days, \( p = 0.014 \)). 78.8% (26/33) of patients receiving immunotherapy within less than 7 days had a monophasic course (Figure 1B), compared to 38.5% (10/26) of those who did not receive any immunotherapy within less than 7 days \( (p = 0.002) \) (Figure 1C). Relapsing patients had a shorter median duration of corticosteroid treatment at first event (median 3.8 vs 6 weeks, \( p = 0.014 \)).

**Multivariable Logistic Regression**

Fifty-eight patients were included in the multivariable logistic regression model for relapsing disease course (Table 2). Early initiation of immunotherapy at first disease event (<7 days from symptom onset) was independently associated with 6.7-fold reduced odds of relapsing disease course (OR 0.15, 95% CI 0.03–0.61, \( p = 0.009 \)). Use of corticosteroid treatment for 5 weeks or longer at first event was independently associated with 6.7-fold reduced odds of relapsing course (OR 0.15, 95% CI 0.03–0.80, \( p = 0.026 \)). Presence of abnormal optic nerves on MRI at first event was independently associated with 12.5-fold reduced odds of relapsing course (OR 0.08, 95% CI 0.01–0.50, \( p = 0.007 \)). Figure 2 shows the estimated probability of relapse-free survival according to time from disease onset. 61.5% (16/26) of patients with relapsing disease course had their first relapse within 1 year of disease onset. Among those with relapsing disease and abnormal optic nerves on initial MRI, 71.4% (5/7) had their first relapse within 6 months of disease onset, compared with 31.3% (5/16) of those with relapsing disease and normal optic nerves on initial MRI \( (p = 0.06 \)).

**Clinical Features and Treatment Factors Associated With Abnormal Neurologic Examination at Final Follow-up**

| Variable | Adjusted odds ratio (95% CI) for relapsing disease course | \( p \) Value |
|----------|--------------------------------------------------|------------|
| Age 12 years or older at disease onset | 1.07 (0.09–12.31) | 0.959 |
| Female sex | 1.18 (0.25–5.52) | 0.834 |
| Abnormal brain on MRI at first disease event | 0.55 (0.06–4.82) | 0.593 |
| Abnormal optic nerves on MRI at first disease event | 0.08 (0.01–0.50) | 0.007 |
| Abnormal spine on MRI at first disease event | 1.21 (0.22–6.66) | 0.829 |
| Immunotherapy <7 days from disease onset | 0.15 (0.03–0.61) | 0.009 |
| ≥5 weeks corticosteroid treatment at first disease event | 0.15 (0.03–0.80) | 0.026 |
| Use of additional noncorticosteroid treatments | 0.55 (0.07–4.30) | 0.568 |

Bold indicates \( p \) values that are statistically significant.
compared with those with monophasic disease (37.5% [9/24] vs 12.8% [5/39], \(p = 0.022\)) (Table 1B). A higher proportion of those with final EDSS \(\geq 1\) had multiple relapses (\(\geq 3\) total disease events) compared with those with final EDSS 0 (50.0% [7/14] vs 14.3% [7/49], \(p = 0.009\)) (Table 1C).

**Multivariable Logistic Regression**

Fifty-four patients were included in the multivariable logistic regression model for abnormal neurologic examination at final follow-up (EDSS \(\geq 1\)) (Table 3). Each 1-point increment in worst EDSS score at first disease event was independently associated with 6.7-fold increased odds of abnormal neurologic examination (EDSS \(\geq 1\)) at final follow-up (OR 6.65, 95% CI 1.33–33.26, \(p = 0.021\)).

**Discussion**

Factors at MOGAD disease onset predictive of a relapsing disease course or final outcome are only partially understood. In this study, we sought to identify early factors at first event of pediatric MOGAD associated with subsequent risk of relapse and final neurologic outcome, with focus on modifiable factors such as treatment.

One of our main findings was the observation that early initiation of immunotherapy at onset (defined using a data-driven threshold of less than 7 days from symptom onset) was independently associated with 6.7-fold reduced odds of subsequent relapsing disease course (\(p = 0.009\)), while controlling for key clinical characteristics, lesion site on onset MRI, and other treatment factors in a multivariable model. Although a role for early treatment in determining final outcome in MOGAD has been hypothesized,\(^6\) and the effects of early immunotherapy have been extensively explored in other neuroinflammatory diseases,\(^{38-43}\) this has not been thoroughly investigated in pediatric MOGAD so far. Our data support the notion that early immunosuppression could be beneficial not just in limiting disability as observed in other conditions but especially in modifying the long-term relapse risk, possibly preventing or reducing the consolidation of a chronic autoimmune reaction within the CNS; although, this remains a speculation based on clinical observations, and definite evidence is lacking. Ongoing progress in refining the clinical and paraclinical characterization of MOGAD including phenotypic expansion\(^{10}\) will be helpful to support early diagnosis of the disorder in the full spectrum of patients. However, it should also be acknowledged that at present, most centers are not able to routinely provide MOG antibody results within a few days;\(^6\) new-onset neuroinflammatory disorders should therefore be treated early and empirically with immunotherapy without waiting for antibody results, in the appropriate clinical context. In this regard, the time to treatment seems to have improved over the years in our cohort, with a

---

**Figure 2 Relapse-Free Survival**

![Graph A](image1.png)  
A. Whole cohort  
![Graph B](image2.png)  
B. Early vs late initiation of immunotherapy at first disease event  
![Graph C](image3.png)  
C. Normal vs abnormal optic nerves on MRI at first disease event  

Kaplan-Meier survival estimates for the first 5 years after disease onset are shown for the whole cohort (panel A, \(n = 75\)) and 2 subgroup comparisons: those with early (<7 days from disease onset, \(n = 37\)) vs late (\(\geq 7\) days from disease onset or no immunotherapy, \(n = 32\)) initiation of first immunotherapy (IT) at first disease event (panel B) and those with normal (\(n = 37\)) vs abnormal (\(n = 35\)) optic nerve (ON) appearance on MRI at first disease event (panel C). Shaded areas indicate 95% confidence interval. \(p\) values were derived from univariate Cox proportional hazards regression.
The second main finding of our study was the observation that use of corticosteroids for 5 weeks or longer at first disease event was independently associated with 6.7-fold reduced odds of relapsing disease course ($p = 0.026$), consistently with previous reports.\textsuperscript{13,16,21,24} The optimal duration of corticosteroid treatment at first event is still debated both in adults and children,\textsuperscript{6,19,25} considering that most patients with MOGAD will have a monophasic disease course and the potential corticosteroid-related side effects but also in view of the observed corticosteroid dependency.\textsuperscript{23} In the light of our results and of previous literature data,\textsuperscript{6,14,21,24} a cautious and slow oral corticosteroid taper in at least 5 weeks (suggested maximum 3 months in the recent European pediatric MOG consortium consensus\textsuperscript{25} and in 3–6 months by other authors\textsuperscript{5}) seems reasonable if well tolerated, possibly partially replaced by monthly IVIG for 3–6 months in case of corticosteroid side effects and also in view of recent favourable data on IVIG in MOGAD.\textsuperscript{6,24}

The analysis of the effect of different treatment combinations, representing a clinical research priority yet to be fully clarified, did not show any significant results in our cohort, although our power to detect such effects was strongly limited by the very small number of patients receiving noncorticosteroid treatments.

Another early factor associated with disease course in our cohort was abnormal optic nerve(s) on MRI at disease onset, which was independently associated with 12.5-fold reduced odds of relapsing disease course ($p = 0.007$). This finding seems contrary to some recent literature data,\textsuperscript{17} although important differences in our study should be highlighted, such as the inclusion of an exclusively pediatric cohort and the fact that abnormal optic nerves on MRI in our study occurred as part of another syndrome in several cases and not just isolated ON.\textsuperscript{17} It should also be noted that, among the patients who did relapse, those with optic nerve involvement at first MRI tended to do so slightly earlier: 71.4% (5/7) had their first relapse within 6 months of disease onset, compared with 31.3% (5/16) of those with normal optic nerves on initial MRI (Figure 2). Whether children with optic nerve involvement represent a specific subset of patients with MOGAD (eTable 2, links.lww.com/NXI/A764), who relapse early but overall less than the rest of the patients, remains only a provisional speculative hypothesis. However, and most importantly, the association of abnormal optic nerve(s) on onset MRI and lower risk of subsequent relapse should be taken with caution, in view of the intrinsic limitations relative to neuroimaging data collection in our study (different MRI scanners, heterogeneous scanning protocols, lack of a central neuroimaging review) which could have strongly influenced our data.

As with other neuroinflammatory disorders,\textsuperscript{42,43} worse severity in the acute phase of first event was associated with greater risk for long-term neurologic sequelae in our cohort: Each 1-point increment in worst EDSS at first attack was independently associated with 6.7-fold increased odds of abnormal neurologic examination at final follow-up (EDSS $\geq 1$) ($p = 0.021$). This supports the idea that early disease events seem highly consequential in patients with MOGAD and onset attack is a major determinant of final disability.\textsuperscript{6,14} as also suggested by the observation that neuronal degeneration biomarkers such as neurofilament light chain (NFL), a marker of axonal damage, increase mostly during this disease phase.\textsuperscript{44}

| Variable | Adjusted odds ratio (95% CI) for EDSS $\geq 1$ at final follow-up | $p$ Value |
|----------|---------------------------------------------------------------|-----------|
| Age 12 years or older at disease onset | 6.96 (0.32–150.26) | 0.216 |
| Female sex | 0.05 (0.00–1.24) | 0.068 |
| Abnormal brain on MRI at first disease event | 0.03 (0.00–3.10) | 0.141 |
| Abnormal optic nerve(s) on MRI at first disease event | 64.20 (0.67–6,189.95) | 0.074 |
| Abnormal spine on MRI at first disease event | 1.80 (0.08–39.68) | 0.710 |
| Immunotherapy $<7$ days from disease onset | 1.84 (0.11–31.95) | 0.675 |
| $\geq 5$ weeks corticosteroid treatment at first disease event | 0.02 (0.00–1.02) | 0.051 |
| Use of additional noncorticosteroid treatments | 0.37 (0.02–7.17) | 0.510 |
| Relapsing disease course | 11.75 (0.76–182.80) | 0.078 |
| Worst EDSS score at first disease event | 6.65 (1.33–33.26) | 0.021 |

Abbreviation: EDSS = Expanded Disability Status Scale. Bold indicates $p$ values that are statistically significant.
Promisingly, serum NfL at first demyelinating event has also been suggested to correlate with neuroradiologic disease burden and risk of subsequent relapse,45 although this was not evaluated in our cohort.

Moreover, in univariate analysis (although not reaching statistical significance in the multivariable model), the proportion of patients with EDSS ≥1 at last follow-up was higher in the subgroup of relapsing patients than in those with monophasic disease (p = 0.022), suggesting an additional negative effect of cumulative disease attacks on final outcome, consistent with previous literature data6,8 but warranting further confirmation.

The overall characteristics of our cohort reflect the pertinent literature, with no obvious racial bias nor sex preponderance6,14 and ADEM being the most common type of presentation, especially among younger patients.9,17,23 ON being preponderant in older children, and with limited representation of other clinical phenotypes, such as TM, NMO, and encephalitis.9 As regards investigations, brain involvement at onset MRI was slightly more frequent in younger children, as already described in the literature,6,9 and nearly half of the patients in our cohort, regardless of the overall main clinical syndrome, had optic nerve involvement at first MRI. In these latter patients, there was a high proportion of bilateral optic nerve involvement, longitudinal optic nerve involvement for at least half of its length, and optic nerve head swelling, reflecting the known features of MOG-associated ON.14,23,46-48 CSF-restricted OCBs49 were found in less than 1 every 5 patients in our cohort,6 slightly more frequently in younger children.17 In our cohort, and similar to the literature, 40.0% of children relapsed,15 with 24.6% experiencing multiple relapses, often spanning over several years15; however, most (61.5%) of those with relapsing disease had their first relapse within 1 year of disease onset,15 with higher rate of short-term relapses in older patients. Final outcome was overall favourable in most of our patients similar to other pediatric data and generally better compared with adult MOGAD cohorts.6,16

The main strengths of our study are the collection of detailed data on clinical characteristics, treatments, and importantly treatment timing and duration, from a multicenter collaboration including the main centers treating pediatric neuroinflammatory disorders in Italy with wide representation of all the country (eFigure 1, links.lww.com/NXI/A764), giving us confidence that referral bias is unlikely and the full spectrum of pediatric MOGAD (including less severe and monophasic cases) is represented. Limitations include the retrospective nature of data collection, the modest number of patients to power statistical analyses, and a lack of complete homogeneity as regards antibody testing (i.e., live vs fixed CBA and data on the type of assay not available in a few cases), also because of the large span of disease onset (2008–2022). Moreover, antibody titres at onset and at follow-up were heterogeneously available in our cohort; therefore, they were not analyzed. Neuroimaging data were also strongly limited by the use of different scanners, heterogeneous protocols, and the lack of a central review (neuroimaging data were assessed based on the available official neuroimaging reports). Similarly, EEG data was not reviewed centrally. Moreover, follow-up duration was significantly longer in relapsing than in monophasic patients. Finally, the inherent limitations of the clinical neurologic score used (EDSS) should be acknowledged, especially for patients on ON. Therefore, our results warrant confirmation in larger, and ideally prospective, cohorts.

This study represents a real-life multicenter investigation of pediatric MOGAD, with focus on the relationship between early factors at disease onset and subsequent risk of relapse and poor outcome.

In our cohort, early treatment, longer duration of corticosteroid therapy (≥5 weeks), and abnormal optic nerve at MRI at first event were significantly associated with reduced risk of subsequent relapse, highlighting the importance of adequate timing and duration of immunotherapy. Whereas, the main determinant of final outcome was the severity of disease at first event, with additional negative effect of cumulative additional attacks (only shown at univariate analysis in our cohort, to be confirmed by further studies).

In clinical practice, the identification of early markers for disease course and outcome are useful to inform family counselling and most importantly to guide a more personalized and targeted disease monitoring and treatment, offering the unique potential of intervening in the natural history of the disease.

Acknowledgment
The authors thank the Paediatric Research Institute “Città della Speranza,” Padova, Italy, and the project “MUSICA”.

Study Funding
The authors report no targeted funding.

Disclosure
The authors report no relevant disclosures. Go to Neurology.org/NN for full relevant disclosures.

Publication History
Received by Neurology: Neuroimmunology & Neuroinflammation May 15, 2022. Accepted in final form July 26, 2022. Submitted and externally peer reviewed. The handling editor was Josep O. Dalmau, MD, PhD, FAAN.

Appendix Authors

| Name                  | Location                                      | Contribution                                      |
|-----------------------|-----------------------------------------------|--------------------------------------------------|
| Margherita Nosadini, MD, PhD | Paediatric Neurology and Neuroradiology Unit, Department of Women's and Children's Health, University Hospital of Padova, Italy; Neuroimmunology Group, Paediatric Research Institute “Città della Speranza,” Padova, Italy | Project conception, design, and modifications; data acquisition; access to all data and responsibility for the data, accuracy of the data analysis, and the conduct of the research; data interpretation; draft preparation, editing and approval of final draft |

Continued
## Appendix (continued)

| Name                  | Location                                                                 | Contribution                                                                                      |
|-----------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Michael Eyre, MD      | School of Biomedical Engineering and Imaging Sciences, King's College London; Children's Neurosciences, Evelina Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom | Access to all data; data analysis and interpretation; editing and approval of final draft          |
| Thea Giacomini, MD    | Unit of Child Neuropsychiatry, Clinical and Surgical Neurosciences Department, IRCCS Giannina Gaslini Institute, Genoa, Liguria, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Massimiliano Valeriani, MD | Neurosciences Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Marida Della Corte, MD | Department of Neurosciences, Pediatric Neurology, Santobono-Pausilipon Children's Hospital, Via M. Fiore 6, 80129, Naples, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Andrea Domenico Pratico, MD PhD | Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, University of Catania, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Pietro Annovazzi, MD  | Multiple Sclerosis Center, ASST della Valle Olona, Hospital of Gallarate, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Ramona Cordani, MD    | Unit of Child Neuropsychiatry, Clinical and Surgical Neurosciences Department, IRCCS Institute Giannina Gaslini, Genoa, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Duccio Maria Cordelli, MD | Child Neurology and Psychiatry Unit, Department of Medical and Surgical Sciences (DIMEC), S. Orsola Hospital, University of Bologna, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Giovanni Crichiuitti, MD | Division of Pediatrics, Department of Medicine, University Hospital of Udine, Piazzale S.M. della Misericordia 15, 33100 Udine, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Gabriella Di Rosa, MD | Unit of Child Neurology and Psychiatry, Department of Human Pathology of the Adult and Developmental Age "Gaetano Barresi", University of Messina, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Valentina Dolciemascolo, MD | Division of Pediatrics, Department of Medicine, University Hospital of Udine, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Anna Fetta, MD        | Child Neurology and Psychiatry Unit, Department of Medical and Surgical Sciences (DIMEC), S. Orsola Hospital, University of Bologna, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Elena Freri, MD       | Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Paolo Gallo, MD, PhD  | Multiple Sclerosis Centre, Neurology Clinic, Department of Neurosciences, Università degli Studi di Padova, Italy | Participation in the patient management; data interpretation; editing and approval of final draft |
| Matteo Gastaldi, MD   | Neuroimmunology Laboratory, IRCCS Mondino Foundation, Pavia, Italy         | Data acquisition and interpretation; editing and approval of final draft                           |
| Tiziana Granata, MD   | Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Luisa Grazian, MD     | Unit of Pediatrics, ULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Raffaele Iorio, MD, PhD | Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Martina Lombardini, MD | Child Neurology Unit and Laboratories, Neurosciences Department, Meyer Children's University Hospital, Florence, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Monica Margoni, MD, PhD | Multiple Sclerosis Centre, Neurology Clinic, Department of Neurosciences, Università degli Studi di Padova, Italy | Participation in the patient management; data interpretation; editing and approval of final draft |
| Sara Mariotto, MD, PhD | Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico GB Rossi, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
| Sara Matricardi, MD, PhD | Child Neurology and Psychiatry Unit, "G. Salesi" Children's Hospital, Ospedali Riuniti Ancona, Ancona, Italy | Data acquisition and interpretation; editing and approval of final draft                           |
### Appendix (continued)

| Name                  | Location                                                                 | Contribution                                                                                           |
|-----------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Federico Melani, MD   | Child Neurology Unit and Laboratories, Neuroscience Department, Meyer Children's University Hospital, Florence, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Nardo Nardocci, MD, PhD | Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Laura Papetti, MD     | Neuroscience Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Alice Passarini, MD   | Child Neuropsychiatry Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano | Data acquisition and interpretation; editing and approval of final draft                                  |
| Francesco Pisani, MD   | Child Neuropsychiatry Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Chiara Po', MD        | Unit of Pediatrics, ULSS 2 Marina Trevigiana, Ca' Foncello Hospital, Treviso, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Marco Puthenparamplil, MD, PhD | Multiple Sclerosis Centre, Neurology Clinic, Department of Neuroscience, Università degli Studi di Padova, Italy | Participation in the patient management; data interpretation; editing and approval of final draft        |
| Francesca Ragona, MD  | Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Salvatore Savasta, MD | Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Sabrina Siliquini, MD | Child Neurology and Psychiatry Unit, "G. Salesi" Children's Hospital, Ospedali Riuniti Ancona, Ancona, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Irene Toldo, MD, PhD  | Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Alessandra Tozzo, MD  | Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Emanuela Claudia Turco, MD | Child Neuropsychiatry Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Antonio Varone, MD    | Pediatric Neurology, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Alberto Vogrig, MD, PhD | Clinical Neurology, Azienda Ospedaliero Universitaria Friuli Centrale, Udine, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Luigi Zuliani, MD, PhD | Department of Neurology, Ospedale San Bortolo, Azienda ULSS8 Berica, Vicenza, Italy | Participation in the patient management; data interpretation; editing and approval of final draft        |
| Samuela Bugin, MD     | U.O.C. Pediatria, Ospedale San Bortolo, Vicenza, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Sara Rossato, MD, PhD   | U.O.C. Pediatria, Ospedale San Bortolo, Vicenza, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Alessandro Orsini, MD | Pediatric Neurology, Pediatric University Department, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Gaetano Cantalupo, MD, PhD | Child Neuropsychiatry, Department of Surgical Sciences, Dentistry, Gynaecology and Paediatrics, University of Verona, Verona, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Maria Margherita Mancardi, MD, PhD | Unit of Child Neuropsychiatry, Clinical and Surgical Neurosciences Department, IRCCS Giannina Gaslini Institute, Genoa, Genoa, Liguria, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Michela Ada Noris Ferrili, MD | Neuroscience Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Thomas Foiadelli, MD  | Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy | Data acquisition and interpretation; editing and approval of final draft                                  |
| Stefano Sartori, MD, PhD | Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova, Italy; Neuroimmunology Group, Paediatric Research Institute “Città della Speranza,” Padova, Italy | Project conception, design, and modifications; data acquisition; access to all data and responsibility for the data, accuracy of the data analysis, and the conduct of the research; data interpretation; draft preparation, editing and approval of final draft |
Lower Risk of Relapsing Disease Course in Pediatric MOGAD
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With
Margherita Nosadini, Michael Eyre, Thea Giacomini, et al.
Neurol Neuroimmunol Neuroinflamm 2023;10;
DOI 10.1212/NXI.00000000000200065

This information is current as of November 29, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/10/1/e200065.full.html

References
This article cites 48 articles, 15 of which you can access for free at:
http://nn.neurology.org/content/10/1/e200065.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus